Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | MicrobiomeTrials← Back to trialsNCT07780838
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-11-01Est. Completion: 2027-12-31
Enrollment target: 29 participants Locations- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Other microbiome trials you might be interested in
Uterine NeoplasmsUterine Cervical NeoplasmsBiliary Tract NeoplasmsUrologic NeoplasmsCarcinoma, Non-Small-Cell LungHER2 Mutations Breast Neoplasms
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than…
Phoenix, United StatesEst. completion Nov 1, 2023
Pancreatic AdenocarcinomaAmpulla of Vater CarcinomaAdrenocortical Carcinoma
Neuroendocrine Carcinoma
Soft Tissue Sarcoma
Small Bowel Adenocarcinoma
Duodenum Adenocarcinoma
Gastric Adenocarcinoma
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immun…
Angers, FranceEst. completion Oct 2028